First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Total Assets
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued total assets. Based on the latest financial reports, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) holds total assets worth $290.58 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TRAXV company net worth for the company's overall valuation and market capitalisation.
Total Assets of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
Total assets of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's total assets have evolved over time, based on quarterly financial data. See First Tracks Biotherapeutics, Inc. Ordin stock quote for real-time trading data and today's change.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Asset Composition Analysis
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Total Assets Breakdown (December 2024)
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued total assets breakdown as of December 2024. First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's total assets of $290.58 Million consist of 88.2% current assets and 11.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2024)
This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TRAXV current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's current assets represent 88.2% of total assets in 2024, a decrease from 89.7% in 2023.
- Cash Position: Cash and equivalents constituted 27.9% of total assets in 2024, up from 8.1% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Competitors by Total Assets
Key competitors of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.74 | - | - |
| Quick Ratio | 8.74 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $256.29 Million | - | - |
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Advanced Valuation Insights
This section examines the relationship between First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 1.39 |
| Asset Growth Rate (YoY) | -0.5% |
| Total Assets | $441.89 Million |
| Market Capitalization | $613.49 Million USD |
Valuation Analysis
Above Book Valuation: The market values First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's assets above their book value (1.39x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's assets decreased by 0.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below shows the annual total assets of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $441.89 Million | -0.50% |
| 2023-12-31 | $444.11 Million | -- |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more